NCT00942994View on ClinicalTrials.gov

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

412

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

March 31, 2010

Conditions
Hypertension
Interventions
DRUG

Aliskiren/Amlodipine

"Amlodipine capsule (5 mg)~Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)"

DRUG

Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)

"Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)~HCTZ capsule (12.5 mg, 25mg)"

Trial Locations (5)

20110

Manassas Clinical Research Center, Manassas

33143

Well Pharma Medical Research, South Miami

72201

K and S Research Services, Little Rock

98133

Scriber Kidney Center, Seattle

02126

Hyde Park Health Associates, Mattapan

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00942994 - Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension | Biotech Hunter | Biotech Hunter